SOUTH
SAN FRANCISCO, Calif., July 9, 2024
/PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today
announced that it intends to offer and sell up to $200.0 million of shares of its common stock and,
in lieu of common stock, to offer and sell to certain investors
pre-funded warrants to purchase its common stock in an underwritten
public offering. In addition, IDEAYA intends to grant the
underwriters a 30-day option to purchase up to $30.0 million of shares of its common stock. The
offering is subject to market and other conditions, and there can
be no assurance as to whether or when the offering may be
completed, or as to the actual size or terms of the offering.
J.P. Morgan, Goldman Sachs & Co. LLC, Jefferies and RBC
Capital Markets are acting as joint book-running managers for the
offering.
The securities described above are being offered by IDEAYA
pursuant to an automatically effective shelf registration statement
on Form S-3 that was previously filed with the U.S. Securities
and Exchange Commission, or the SEC. The offering will be made
only by means of a written prospectus and a prospectus supplement
that form a part of the registration statement. A preliminary
prospectus supplement and accompanying prospectus relating to and
describing the terms of the offering will be filed with
the SEC and will be available on the SEC's website. When
available, copies of the preliminary prospectus supplement and the
accompanying prospectus relating to these securities may also be
obtained by request from: J.P. Morgan, by mail at J.P. Morgan
Securities LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717,
or by email at prospectus-eq_fi@jpmorganchase.com and
postsalemanualrequests@broadridge.com; Goldman Sachs & Co.
LLC by mail at Goldman Sachs & Co. LLC, Attention: Prospectus
Department, 200 West Street, New York, NY 10282, or by
telephone at 866-471-2526, or by email
at prospectus-ny@ny.email.gs.com; Jefferies, by mail at
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, New York, NY
10022, or by telephone at 877-547-6340 or 877-821-7388, or by email
at Prospectus_Department@Jefferies.com; or RBC Capital Markets, by
mail at RBC Capital Markets, LLC, Attention: Equity Capital
Markets, 200 Vesey Street, 8th Floor, New York, NY 10281, or by telephone at
877-822-4089, or by email at equityprospectus@rbccm.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
___________________
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the
discovery and development of targeted therapeutics for patient
populations selected using molecular diagnostics. IDEAYA's approach
integrates capabilities in identifying and validating translational
biomarkers with drug discovery to select patient populations most
likely to benefit from its targeted therapies. IDEAYA is applying
its research and drug discovery capabilities to synthetic lethality
– which represents an emerging class of precision medicine
targets.
___________________
Legal Notice Regarding Forward-Looking
Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein, including without limitation statements regarding the offer
and sale of securities, the terms of the offering and ability to
complete the offering, are forward-looking statements reflecting
the current beliefs and expectations of management made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements involve
substantial risks and uncertainties that could cause IDEAYA's
preclinical and clinical development programs, future results,
performance or achievements to differ significantly from those
expressed or implied by the forward-looking statements. Such risks
and uncertainties include, among others, risks and uncertainties
related to market conditions and the satisfaction of closing
conditions related to the proposed public offering, the
uncertainties inherent in the drug development process, including
IDEAYA's programs' early stage of development, the process of
designing and conducting preclinical and clinical trials, serious
adverse events, undesirable side effects or unexpected
characteristics of drug development candidates, the regulatory
approval processes, the timing of regulatory filings, the
challenges associated with manufacturing drug products, IDEAYA's
ability to successfully establish, protect and defend its
intellectual property and other matters that could affect IDEAYA's
ability to complete the offering and the sufficiency of existing
cash to fund operations. IDEAYA undertakes no obligation to update
or revise any forward-looking statements. For a further description
of the risks and uncertainties that could cause actual results to
differ from those expressed in these forward-looking statements, as
well as risks relating to the business of IDEAYA in general, see
IDEAYA's current and future filings with the SEC, including its
Annual Report on Form 10-K filed on February
20, 2024, Quarterly Report on Form 10-Q filed on
May 7, 2024 and preliminary
prospectus supplement related to the proposed public offering.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants-302192551.html
SOURCE IDEAYA Biosciences, Inc.
